The Breast Cancer Prevention Trial (BCPT) was designed to see whether taking the drug tamoxifen (Nolvadex®) could prevent breast cancer in women who are at an increased risk of developing the disease. The BCPT was also looking at whether taking tamoxifen decreases the number of heart attacks and reduces the number of bone fractures in these women (see the protocol summary).
The study began recruiting participants in April 1992 and closed enrollment in September 1997; 13,388 women ages 35 and older were enrolled. Researchers with the National Surgical Adjuvant Breast and Bowel Project (NSABP) conducted the study at more than 300 centers across the United States and Canada. The study (also called the P-1 trial) was funded by the National Cancer Institute (NCI), the United States' primary agency for cancer research.
This text may be reproduced or reused freely. Please credit the National Cancer Institute as the source. Any graphics may be owned by the artist or publisher who created them, and permission may be needed for their reuse.